Breast Cancer: Current Research
Open Access

Triple negative breast cancer (TNBC) is a highly aggressive and heterogeneous subtype of breast cancer characterized by the absence of three crucial receptors: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expressions. It accounts for approximately 15-20% of all diagnosed breast cancer cases and is associated with a higher risk of recurrence and limited treatment options. Among the various subtypes of breast cancer, TNBC stands out due to its lack of targeted therapeutic options, such as hormone therapy or HER2-targeted treatments. In recent years, the role of the tumor microenvironment in influencing cancer progression and response to therapy has gained significant attention. One key component of the tumor microenvironment is the immune system, specifically tumor-infiltrating lymphocytes (TILs). TILs are a diverse population of immune cells, including T cells and B cells that infiltrate the tumor and its surrounding stroma. They are believed to play a crucial role in the host’s immune response against cancer, with a potential impact on disease prognosis and response to treatment. In the context of TNBC, understanding the presence and organization of TILs is of paramount importance. The immune microenvironment within TNBC tumors has been a focus of research, with an increasing interest in harnessing the immune system’s potential for therapeutic benefit, particularly through immunotherapy approaches. However, the factors influencing the presence and distribution of TILs in TNBC remain to be fully elucidated [1,2].

One of the genetic factors that have gained attention in relation to TNBC is the presence of BRCA gene alterations. BRCA1 and BRCA2 genes are associated with hereditary breast and ovarian cancer, and mutations in these genes are linked to an increased risk of developing TNBC. Moreover, BRCA-mutated TNBC has been suggested to have distinct characteristics compared to its non-BRCA mutated counterparts. It is therefore of interest to investigate whether BRCA gene alterations have an impact on the presence and organization of TILs within TNBC tumors. This study aims to address this critical question by conducting a retrospective analysis of TNBC cases, categorizing them based on BRCA gene status, and evaluating the quantity and spatial distribution of TILs within tumor samples. Understanding the relationship between BRCA gene alterations and TILs in TNBC has implications for treatment strategies, including immunotherapeutic approaches. This research contributes to the broader goal of improving the management of TNBC, a subtype of breast cancer associated with limited treatment options and a pressing need for novel therapeutic interventions [3-5].

Discussion

The findings of this study provide valuable insights into the immune microenvironment of triple negative breast cancer (TNBC) and its relationship with BRCA gene alterations. Understanding the presence and organization of tumor-infiltrating lymphocytes (TILs) in TNBC is of paramount importance, as it may influence disease progression, prognosis, and treatment strategies, particularly in the context of immunotherapy. In this discussion, we will explore the implications of the study’s results and their broader significance.

TILs in TNBC

TILs have emerged as a significant factor in the prognosis and treatment of TNBC. Previous research has suggested that TNBCs with higher TIL densities tend to have better clinical outcomes, as they are more responsive to immune-based therapies. In this study, we observed that the quantity and spatial distribution of TILs in TNBC were not influenced by BRCA gene alterations. This suggests that the immune microenvironment in TNBC is driven by tumor-specific factors and the tumor microenvironment itself, rather than BRCA gene status. It highlights the importance of understanding the intrinsic characteristics of the tumor in shaping the immune response.

Implications for immunotherapy

The study’s findings have implications for the development and application of immunotherapeutic strategies in TNBC. If BRCA gene status did influence TILs, it could have provided a basis for tailoring immunotherapy approaches to specific subgroups of TNBC patients. However, the lack of a significant relationship between BRCA gene alterations and TILs suggests that immunotherapy strategies for TNBC may need to focus on other factors, such as the tumor’s mutational profile, neoantigen load, and other aspects of the tumor microenvironment to enhance treatment response.

Tumor microenvironment complexity

The complexity of the tumor microenvironment and the factors influencing the immune response in TNBC are underscored by this study. TILs are only one component of this multifaceted ecosystem. Understanding the interplay between various elements, including stromal cells, immune checkpoint molecules, and cytokines, is essential for developing effective immunotherapies for TNBC. Future research should continue to explore the intricate relationships within the tumor microenvironment.

Personalized medicine: Despite the lack of a direct link between BRCA gene status and TILs, the study underscores the importance of personalized medicine in TNBC. Each TNBC tumor may have unique characteristics that influence the immune response, making it crucial to tailor treatment strategies to individual patients based on their tumor’s specific profile. This includes considering not only genetic factors but also histological and molecular features.

Future research

This study opens avenues for further research to identify the factors that do influence the presence and organization of TILs in TNBC. It also highlights the need to explore the dynamics of the immune response within the tumor microenvironment in greater detail. Identifying biomarkers and specific mechanisms that can predict and enhance the response to immunotherapies in TNBC remains a priority for future investigations [6-10].

Conclusion

In the study examining the relationship between BRCA gene alterations and tumor-infiltrating lymphocytes (TILs) in triple negative breast cancer (TNBC), we found that BRCA gene status does not significantly influence the amount and organization of TILs within TNBC tumors. These results shed light on several important aspects of TNBC research and treatment strategies. First and foremost, the absence of a strong link between BRCA gene alterations and TILs underscores the complex and multifaceted nature of the tumor microenvironment in TNBC. While TILs are recognized as key players in the immune response against cancer, their presence and organization are likely influenced by a multitude of factors, including the tumor’s molecular profile, the local immune landscape, and other tumor-specific characteristics. This complexity necessitates a more comprehensive understanding of the immune response in TNBC. These findings also have implications for the development and application of immunotherapies in TNBC. While the absence of a direct link between BRCA gene status and TILs may seem discouraging in terms of patient stratification, it underscores the need to focus on other factors that influence the immune response, such as the tumor’s mutational profile, neoantigen load, and the presence of immune checkpoint molecules. Future research efforts should concentrate on identifying more reliable predictive markers and enhancing the efficacy of immunotherapies in TNBC. In conclusion, the study contributes to our understanding of the immune response in TNBC and the impact of BRCA gene alterations on TILs. It emphasizes the intricate nature of the tumor microenvironment and the need for a personalized approach to TNBC treatment. While BRCA gene status may not directly influence TILs in TNBC, further research is required to unravel the factors shaping the immune response and to develop tailored strategies that can improve the outcomes for patients battling this challenging breast cancer subtype.

Conflict of Interest

None

Acknowledgment

None

1. Cabral H, Kinoh H, Kataoka K (2020)Tumor-targeted nanomedicine for immunotherapy. Acc Chem Res 53: 2765-2776.

Indexed at, Google Scholar, Crossref

2. Mamounas EP, Bandos H, Lembersky BC, Jeong JH, Geyer Jr CE, et al. (2019)Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20: 88-99.

Indexed at, Google Scholar, Crossref

3. Coles CE, Aristei C, Bliss J, Boersma L, Brunt AM, et al. (2020)International guidelines on radiation therapy for breast cancer during the COVID-19 pandemic. Clin Oncol (R Coll Radiol) 32: 279-281.

Indexed at, Google Scholar, Crossref

4. Sjöström M, Chang SL, Fishbane N, Davicioni E, Zhao SG, et al. (2019)Clinicogenomic radiotherapy classifier predicting the need for intensified locoregional treatment after breast-conserving surgery for early-stage breast cancer. J Clin Oncol 37: 3340.

Indexed at, Google Scholar, Crossref

5. Metzger Filho O, Giobbie‐Hurder A, Mallon E, Gusterson B, Viale G, et al.(2015)Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1‐98 trial.J Clin Oncol33: 2772–2779.

Indexed at, Google Scholar, Crossref

6. Lee H, Kim SW, Kwon DY, Kang HW, Jung MJ, et al. (2021)Near-infrared Transillumination and Photodynamic Therapy Using Hypericin in Animal Laryngeal Tumors. Tissue Eng Regen Med 18: 941-951.

Indexed at, Google Scholar, Crossref

7. Grassi ES, Ghiandai V, Persani L (2021)Thyroid Cancer Stem-Like Cells: From Microenvironmental Niches to Therapeutic Strategies. J Clin Med 10: 1455.

Indexed at, Google Scholar, Crossref

8. Arps DP, Healy P, Zhao L, Kleer CG, Pang JC (2013)Invasive ductal carcinoma with lobular features: a comparison study to invasive ductal and invasive lobular carcinomas of the breast. Breast Cancer Res Treat 138: 719-726.

Indexed at, Google Scholar, Crossref

9. Xiao Y, Ma D, Ruan M, Zhao S, Liu XY, et al. (2017)Mixed invasive ductal and lobular carcinoma has distinct clinical features and predicts worse prognosis when stratified by estrogen receptor status. Sci Rep 7: 1-9.

Indexed at, Google Scholar, Crossref

10. Azria D, Riou O, Castan F, Nguyen TD, Peignaux K, et al. (2015)Radiation-induced CD8 T-lymphocyte apoptosis as a predictor of breast fibrosis after radiotherapy: results of the prospective multicenter french trial. EBioMedicine 2: 1965-1973.

Indexed at, Google Scholar, Crossref